Authors
Latest:
Dr. Coveler on Replacing 5-FU With NUC-3373 in mCRCAndrew Coveler, MD, discusses the potential clinical implications of positive data with NUC-3373 in metastatic colorectal cancer.
Latest:
Dr Halpern on Addressing Unmet Needs in MyelofibrosisAnna B. Halpern, MD, discusses ongoing efforts to address unmet needs in patients with primary myelofibrosis.
Latest:
Dr Kitko on the Utility of Obe-Cel in Pediatric Patients With B-ALLCarrie L. Kitko, MD, discusses the use of obecabtagene autoleucel for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Latest:
Ovarian Cancer Prevention With the Opportunistic Salpingectomy: An Opportunity for Multidisciplinary CollaborationA new understanding of pathogenesis has given rise to a promising prevention strategy for women at an average risk of developing ovarian cancer through surgical removal of the fallopian tubes, referred to as an opportunistic salpingectomy.
Latest:
Dr Quiroga on the Emergence of HER2-Low in Breast CancerDionisia Quiroga, DO, PhD, discusses the emergence of the HER2-low categorization in breast cancer as well as current treatment options for patients with HER2-low disease.
Latest:
Dr Wander on Managing HR+ Advanced Breast Cancer in the ClinicSeth Wander, MD, PhD, discusses how he approaches therapeutic treatment for patients with ER+ advanced breast cancer in the clinic.
Latest:
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm DPreliminary results for treatment with zanubrutinib + venetoclax in patients with high-risk TN CLL/SLL with del(17p) and/or TP53 mutation showed Promising efficacy in a high-risk population with deep and durable responses according to data from arm D of the phase 3 SEQUOIA trial (NCT03336333).
Latest:
Dr Wu on the Role of METTL3-Mediated m6A Modification in CLL ProgressionYiming Wu, PhD, discusses a study identifying METTL3-mediated N6-methyladenosine modification as a key translational regulator of splicing factors, and how this mechanism contributes to the progression of chronic lymphocytic leukemia.
Latest:
Treating R/R Advanced Bladder Cancer With Novel Sequencing StrategiesUCSF Health’s Vadim S. Koshkin, MD, highlights approaches for sequencing novel therapies into treatment algorithms for patients with relapsed/refractory advanced bladder cancer.
Latest:
Differentiation Therapy in Acute Myeloid Leukemia: Not Just for APL AnymorePamela J Sung, MD, PhD, details differentiation therapy in acute myeloid leukemia, focusing on newer targets and preclinical evidence for a novel FLT3 combination.
Latest:
Dr. Kim on the Future Role of Y-90 in Patients with Unresectable HCCEdward Kim, MD, discusses the future role of Y-90 in patients with unresectable hepatocellular carcinoma.
Latest:
Dr Fujiwara on the FDA Approval of Tisotumab Vedotin for Recurrent Cervical CancerKeiichi Fujiwara, MD, PhD, discusses the significance of the FDA approval of tisotumab vedotin for patients with recurrent or metastatic cervical cancer.
Latest:
The Importance of Oral Medicine in Cancer: Evaluation and TreatmentAlessandro Villa, DDS, PhD, MPH, discusses the importance of oral medicine in cancer treatment.
Latest:
Q&A: Final Questions on Glioblastoma and NeuroimagingNathalie Albert, MD, and Matthias Preusser, MD, address audience questions and share their insights on promising and anticipated advancements in neuroimaging techniques, highlighting the potential impact of these emerging strategies on the diagnosis, monitoring, and treatment of glioblastoma.
Latest:
Dr. Kallam on the Role of BTK and PI3K Inhibitors in CNS LymphomaAvyakta Kallam, MBBS, discusses the role of BTK and PI3K inhibitors in the treatment of patients with central nervous system lymphoma.
Latest:
Dr. Adashek on Targeting Molecular Alterations to Treat Multiple Tumor TypesJacob J. Adashek, DO, discusses how targeting molecular alterations is key for treating multiple types of cancer.
Latest:
ASCO GI 2021: MRD Detection With ctDNA From AssaysExpert physicians discuss data presented at the ASCO GI (American Society of Clinical Oncology Gastrointestinal Cancers Symposium) 2021 annual meeting, regarding minimal residual disease (MRD) detection with ctDNA (circulating tumor DNA) from personalized assays in stage II and III patients with colorectal cancer.
Latest:
Dr. Zakrzewski on Investigation of IT848 Nanotherapy in Hematologic MalignanciesJohannes Zakrzewski, MD, discusses the investigation of a nanoframework-based delivery system for IT848 in hematologic malignancies.
Latest:
Dr Morgans on Recent Adjustments to Medicare Part D to Improve Treatment Access in Prostate CancerAlicia Morgans, MD, MPH, discusses recent adjustments to Medicare Part D rules, emphasizing their positive impact on out-of-pocket costs for patients with prostate cancer.
Latest:
Dr Siu on the Rationale for Combining Petosemtamab With Pembrolizumab in HNSCCLillian L. Siu, MD, FRCPC, discusses the background for evaluating first-line petosemtamab plus pembrolizumab in recurrent/metastatic PD-L1+ HNSCC.
Latest:
Fellows on Film: How To Market Yourself for a FellowshipRichard J. Bleicher, MD, FACS, and Salvatore Nardello, DO, discuss how to market oneself for a fellowship in oncology.
Latest:
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual MeetingExperts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeting.
Latest:
Key Takeaways For Treating Patients Diagnosed With CholangiocarcinomaProvider and patient perspectives on why patient education about FGFRi treatment-associated adverse events and how to manage them are is essential in helping patients maintain a good quality of life and stay on treatment.
Latest:
Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin LymphomaDrs Lunning and Rutherford discuss findings from the ECHELON-1 trial of BV-AVD in the cohort of patients with Hodgkin lymphoma over 60 years of age.
Latest:
Dr. Duval on the Use of MSI-H as a Biomarker of Response in Patients With CancerAlex Duval, MD, PhD, discusses the use of microsatellite instability–high as a biomarker of response to therapy in patients with cancer.
Latest:
Dr. Eakin on Racial Disparities in Uterine CancerCortney Eakin, MD, discusses racial disparities and histology trends in uterine cancer.
Latest:
Dr. Stanton on Improving Responses to Immunotherapy in Early-Stage HR+ Breast CancerSasha Stanton, MD, discusses efforts to improve the responses to immunotherapy regimens in early-stage hormone receptor–positive breast cancer.
Latest:
BTK Inhibitors, CAR T-Cell Therapy Drive Paradigm Changes in Follicular LymphomaAdvancements in FL treatment, including BTK inhibitors and CAR T-cell therapies, offer new hope for relapsed or refractory cases.
Latest:
Taking Action to Individualize Ovarian Cancer Care: Key TakeawaysIn this fifth episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, share key takeaways from their discussion on how to best individualize care for patients with ovarian cancer.
Latest:
Dr. Rose on the Results of the BEAVER Trial in Non-V600E BRAF-Mutant Advanced Solid TumorsApril Rose, MD, discusses the efficacy results of the ongoing phase 2 BEAVER trial in non-V600E BRAF-mutant advanced solid tumors.
